Mazdutide: The Dual GLP-1/Glucagon Agonist From Innovent Biologics

For informational purposes only. This article does not constitute medical advice. Consult a qualified healthcare provider for any health-related decisions.

What Is Mazdutide?

Mazdutide (IBI362) is an investigational dual receptor agonist that activates both the GLP-1 receptor and the glucagon receptor. The compound was developed by Innovent Biologics, a Chinese biopharmaceutical company, in collaboration with Eli Lilly and Company. Mazdutide represents one of the most advanced dual agonist programs originating from China and is positioned to address the rapidly growing demand for effective obesity and diabetes therapies in the Chinese market, where the prevalence of overweight and obesity has increased substantially over the past two decades.

The peptide is designed for once-weekly subcutaneous administration and engages the same two-receptor strategy (glucagon + GLP-1) as survodutide, combining GLP-1-mediated appetite suppression and glycemic control with glucagon-mediated energy expenditure and hepatic fat oxidation.

Mechanism of Action

Mazdutide's mechanism follows the dual glucagon/GLP-1 agonist paradigm:

• GLP-1 receptor activation: Provides glucose-dependent insulin secretion, postprandial glucagon suppression, delayed gastric emptying, and central appetite regulation consistent with the GLP-1 receptor agonist class.
• Glucagon receptor activation: Promotes hepatic fat oxidation, increases energy expenditure through thermogenesis, and enhances amino acid catabolism. The glycemic impact of glucagon activation is moderated by the concurrent GLP-1 signaling.

The specific ratio of GLP-1 to glucagon receptor activity in mazdutide may differ from other dual agonists like survodutide, potentially producing a distinct efficacy and tolerability profile. The precise pharmacological characterization continues to be refined through clinical data.

Research Landscape

Phase 3 Data in Chinese Populations

Mazdutide has been evaluated in multiple Phase 3 trials in Chinese populations with obesity and/or type 2 diabetes. Key findings include:

• Obesity trials: Phase 3 data in Chinese adults with obesity demonstrated mean weight reductions of approximately 10-14% at 48 weeks depending on dose, with higher doses showing greater efficacy. A meaningful proportion of participants achieved clinically significant weight loss thresholds (greater than 10% and greater than 15%).
• Type 2 diabetes trials: In patients with type 2 diabetes, mazdutide showed significant HbA1c reductions alongside weight loss, confirming dual metabolic benefit.
• Liver fat reduction: Consistent with the glucagon component's mechanism, studies have shown significant reductions in hepatic fat content.

Chinese Market Context

China represents one of the world's largest and fastest-growing markets for obesity and diabetes therapeutics. With over 200 million adults estimated to have obesity and over 140 million with diabetes, the clinical need is immense. Mazdutide is positioned to be among the first advanced multi-receptor agonists available in China, where access to branded semaglutide and tirzepatide has been more limited than in Western markets.

Key Studies

The Phase 3 registration data for mazdutide in China represent the compound's most important clinical evidence to date. These studies have been designed to support regulatory submissions to the National Medical Products Administration (NMPA) of China, with data presentations at major international conferences providing visibility to the global research community.

Safety Profile

The safety profile of mazdutide in Phase 3 trials has been consistent with other incretin-based dual agonists. Gastrointestinal adverse events (nausea, diarrhea, vomiting) are the most common side effects, occurring in a dose-dependent manner. The rates appear broadly similar to those observed with other GLP-1-based therapies. No unexpected safety signals have been reported in the published data.

Comparison to Related Compounds

Mazdutide shares the same dual glucagon/GLP-1 mechanism as survodutide (Boehringer Ingelheim) but is being developed by a different company and primarily for a different initial market. Compared to tirzepatide (GIP/GLP-1, Eli Lilly), mazdutide substitutes glucagon for GIP receptor activity, which may offer advantages in liver-targeted applications. The competitive landscape among these dual and triple agonists will ultimately be determined by head-to-head efficacy data, safety profiles, pricing, and market access in specific geographies.

Current Status

Mazdutide is in advanced Phase 3 development, with regulatory submissions to Chinese authorities anticipated in the near term. Innovent Biologics retains commercial rights for the Chinese market, while the partnership with Eli Lilly provides potential pathways for broader global development. If approved, mazdutide would be among the first multi-receptor agonists available to the Chinese population and could play a significant role in addressing the country's growing metabolic disease burden.